Gland Celsus Bio Chemicals Profile
Key Indicators
- Authorised Capital ₹ 2.82 Cr
as on 18-01-2025
- Paid Up Capital ₹ 1.65 Cr
as on 18-01-2025
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 1.50 Cr
as on 18-01-2025
- Revenue 26754886.36%
(FY 2020)
- Profit 691537834.88%
(FY 2020)
- Ebitda 516404495.58%
(FY 2020)
- Net Worth 158509.94%
(FY 2020)
- Total Assets 4403500.96%
(FY 2020)
About Gland Celsus Bio Chemicals
- CIN/LLPIN
U74110TG2007PTC053694
- Company No.
053694
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2007
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gland Celsus Bio Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Penmetsa Ravindranath  | Director | 03-Feb-2020 | Current |
Kalidindi Lakshmi  | Director | 03-Feb-2020 | Current |
Financial Performance of Gland Celsus Bio Chemicals.
Gland Celsus Bio Chemicals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 26754886.36% increase. The company also saw a substantial improvement in profitability, with a 691537834.88% increase in profit. The company's net worth Soared by an impressive increase of 158509.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gland Celsus Bio Chemicals?
In 2020, Gland Celsus Bio Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ilabs Info Technology Center (Gurgaon) Private LimitedActive 19 years 7 monthsKalidindi Lakshmi is a mutual person
Valar Capital Advisory LlpActive 6 years 11 monthsPenmetsa Ravindranath and Kalidindi Lakshmi are mutual person
Ksk Energy Ventures LimitedActive 23 years 11 monthsPenmetsa Ravindranath and Kalidindi Lakshmi are mutual person
Dhananjaya Properties LlpActive 10 years 7 daysPenmetsa Ravindranath and Kalidindi Lakshmi are mutual person
- Markanday Properties LlpActive 10 years 7 days
Penmetsa Ravindranath and Kalidindi Lakshmi are mutual person
- Sasikala Properties LlpActive 10 years 6 days
Penmetsa Ravindranath and Kalidindi Lakshmi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 25 Apr 2008 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Gland Celsus Bio Chemicals?
Unlock and access historical data on people associated with Gland Celsus Bio Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gland Celsus Bio Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gland Celsus Bio Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
